Highlights of the new trial results include a response rate of more than 90 percent among pediatric ALL patients, and results from the first lymphoma trials testing the approach, including a 100 percent response rate among follicular lymphoma patients and 45 percent response rate among those with diffuse large B cell lymphoma.